更新于：2024-11-01

poliomyelitis due to poliovirus type I

脊髓灰质炎I型脊髓灰质炎

更新于：2024-11-01

基本信息

别名

poliomyelitis due to poliovirus type I、poliomyelitis due to poliovirus type I (diagnosis)

简介-

关联

项与脊髓灰质炎I型脊髓灰质炎相关的药物

monovalent oral polio vaccine type 1 (mOPV1) (Panacea Biotec)

靶点-

作用机制

免疫刺激剂

在研机构

Panacea Biotec Ltd.

原研机构

Panacea Biotec Ltd.

在研适应症

脊髓灰质炎I型脊髓灰质炎

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期1800-01-20

Poliovirus vaccine live oral bivalent (Panacea Biotec)

靶点-

作用机制

免疫刺激剂

在研机构

Panacea Biotec Ltd.

原研机构

Panacea Biotec Ltd.

在研适应症

脊髓灰质炎I型脊髓灰质炎 [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期1800-01-20

100 项与脊髓灰质炎I型脊髓灰质炎相关的临床结果

登录后查看更多信息

100 项与脊髓灰质炎I型脊髓灰质炎相关的转化医学

登录后查看更多信息

0 项与脊髓灰质炎I型脊髓灰质炎相关的专利（医药）

登录后查看更多信息

项与脊髓灰质炎I型脊髓灰质炎相关的文献（医药）

2012-08-01·The Lancet1区 · 医学

The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001–11: a retrospective analysis

1区 · 医学

Article

作者: Elias Durry ; Tahir P Mir ; Nicholas C Grassly ; Ni'ma Abid ; Obaid ul Islam ; Kathleen M O'Reilly ; Arshad Quddus ; Rudi H Tangermann ; R Bruce Aylward

BACKGROUNDPakistan and Afghanistan are two of the three remaining countries yet to interrupt wild-type poliovirus transmission. The increasing incidence of poliomyelitis in these countries during 2010-11 led the Executive Board of WHO in January, 2012, to declare polio eradication a "programmatic emergency for global public health". We aimed to establish why incidence is rising in these countries despite programme innovations including the introduction of new vaccines.METHODSWe did a matched case-control analysis based on a database of 46,977 children aged 0-14 years with onset of acute flaccid paralysis between Jan 1, 2001, and Dec 31, 2011. The vaccination history of children with poliomyelitis was compared with that of children with acute flaccid paralysis due to other causes to estimate the clinical effectiveness of oral poliovirus vaccines (OPVs) in Afghanistan and Pakistan by conditional logistic regression. We estimated vaccine coverage and serotype-specific vaccine-induced population immunity in children aged 0-2 years and assessed their association with the incidence of poliomyelitis over time in seven regions of Afghanistan and Pakistan.FINDINGSBetween Jan 1, 2001, and Dec 31, 2011, there were 883 cases of serotype 1 poliomyelitis (710 in Pakistan and 173 in Afghanistan) and 272 cases of poliomyelitis serotype 3 (216 in Pakistan and 56 in Afghanistan). The estimated clinical effectiveness of a dose of trivalent OPV against serotype 1 poliomyelitis was 12·5% (95% CI 5·6-18·8) compared with 34·5% (16·1-48·9) for monovalent OPV (p=0·007) and 23·4% (10·4-34·6) for bivalent OPV (p=0·067). Bivalent OPV was non-inferior compared with monovalent OPV (p=0·21). Vaccination coverage decreased during 2006-11 in the Federally Administered Tribal Areas (FATA), Balochistan, and Khyber Pakhtunkhwa in Pakistan and in southern Afghanistan. Although partially mitigated by the use of more effective vaccines, these decreases in coverage resulted in lower vaccine-induced population immunity to poliovirus serotype 1 in FATA and Balochistan and associated increases in the incidence of poliomyelitis.INTERPRETATIONThe effectiveness of bivalent OPV is comparable with monovalent OPV and can therefore be used in eradicating serotype 1 poliomyelitis whilst minimising the risks of serotype 3 outbreaks. However, decreases in vaccination coverage in parts of Pakistan and southern Afghanistan have severely limited the effect of this vaccine.FUNDINGPoliovirus Research subcommittee of WHO, Royal Society, and Medical Research Council.

1993-01-01·International Journal of Epidemiology1区 · 医学

Paralytic Poliomyelitis in Oman: Association between Regional Differences in Attack Rate and Variations in Antibody Responses to Oral Poliovirus Vaccine

1区 · 医学

Article

作者: Ahmed A K Al-Ghassani ; Elizabeth R Zell ; Roland W Sutter ; Musallam S El-Bualy ; Pradeep G Malankar ; Peter A Patriarca ; Shaun Brogan ; Ali Jaffer M Suleiman ; Mark A Pallansch

Variation in attack rates of paralytic disease by region during the 1988-1989 epidemic of type 1 poliomyelitis in Oman provided the stimulus to test the hypothesis that these observations were due to regional differences in the response of infants to trivalent oral poliovirus vaccine (OPV). Seroprevalence studies of 394 children born during the outbreak were conducted in six different regions of Oman and in two socioeconomic status (SES) groups in the capital city of Muscat; a seroconversion study was also carried out in 105 infants born after the outbreak. Seroprevalence rates by region after receipt of at least three doses of OPV ranged from 90% to 100% (median 94%) to poliovirus type 1, and from 86% to 100% (median 97%) to type 2, and from 47% to 79% (median 72%) to type 3, with the lowest rates observed in regions with the highest incidence of type 1 paralytic disease. In Muscat, seroprevalence rates were also significantly lower in low versus high SES groups (type 1: 84% versus 98%, respectively [P = 0.006]; type 3: 59% versus 86%, respectively [P = 0.001]). In the seroconversion study conducted after the outbreak, 89%, 100% and 50% of infants had detectable antibodies to types 1, 2, and 3, respectively, after four doses of OPV. Low responses to type 3 were also associated with the occurrence of sporadic cases of type 3 poliomyelitis in 1991, in spite of high rates of coverage with at least four doses of OPV (> 96%) throughout the country.(ABSTRACT TRUNCATED AT 250 WORDS)

1992-02-15·American Journal of Epidemiology2区 · 医学

Epidemic Poliomyelitis in The Gambia following the Control of Poliomyelitis as an Endemic Disease

2区 · 医学

Article

作者: Yaya Sanyang ; Kebba O. Jaiteh ; Donna Brogan ; Babucarr Sillah ; Elaine W. Flagg ; Ian Forgie ; Phillip Gowers ; Michael S. Deming ; Mac W. Otten

An epidemic of type 1 poliomyelitis involving 305 cases occurred in The Gambia (estimated 1986 population, 768,995) from May through November 1986, following a 6-year period when only five cases were reported. Cases were identified by physician reporting during the epidemic and by a national village-to-village search conducted after the epidemic. The national attack rate was 40 cases per 100,000 people. Cases lived in all parts of the country except the capital, Banjul. The peak month of the epidemic was August (139 cases). The highest attack rate by year of age was in 1-year-old children (394 cases per 100,000 persons), and 75% of cases were 3 years of age or less. A vaccination coverage survey showed that 64% (95% confidence interval 60-68) of 1- to 2-year-old children were vaccinated with at least three doses of trivalent oral polio vaccine at the beginning of the epidemic. Fifty-seven cases became paralyzed more than 2 weeks after a national mass campaign in which 95% of children 1-7 years old were reported to have received a dose of trivalent oral polio vaccine. Experience in The Gambia shows that a several-year period of excellent control of endemic poliomyelitis by a vaccination program can be followed by a major epidemic and that a mass vaccination campaign may be only partially successful in ending the epidemic.